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Iodinated Contrast Media and Cerebral Hemorrhage After
Intravenous Thrombolysis
Niall J.J. MacDougall, MRCP; Ferghal McVerry, MRCP; Sally Baird; Tracey Baird, MRCP;
Evelyn Teasdale, FRCR; Keith W. Muir, MD, FRCP
Background and Purpose—Iodinated contrast is increasingly used in CT perfusion or angiographic examinations in acute
stroke. Increased risk of intracranial hemorrhage (ICH) complicating microcatheter contrast injections has recently been
reported in the second Interventional Management of Stroke (IMS 2) trial with contrast toxicity potentially contributory.
Methods—We reviewed clinical and radiological data on all patients treated with intravenous alteplase at a single center
between May 2003 and November 2008.
Results—Of 312 patients treated with intravenous alteplase, 69 (22.1%) received intravenous iodinated contrast in volumes
between 50 and 150 mL. Incidence of symptomatic ICH defined as per European Cooperative Acute Stroke Study 2 was 16
of 312 (5.1%; 95% CI, 2.7% to 7.6%); among patients not given contrast, it was 12 of 243 (4.9%; 2.2% to 7.7%) compared
with 4 of 69 (5.8%; 0.3% to 11.3%) in those given contrast. Incidence of symptomatic ICH defined as per Safe
Implementation of Thrombolysis in Stroke-MOnitoring Study (SITS-MOST) criteria was 12 of 312 (3.9%; 1.7% to 6%), 9
of 243 (3.7%; 1.3% to 6%) among those not given contrast, and 3 of 69 (4.4%; 95% CI,0.5% to 9.2%) among those given
contrast. Patients with symptomatic ICH were older, had higher pretreatment National Institutes of Health Stroke Scale, and
blood glucose than those without symptomatic ICH. In logistic regression analysis, pretreatment blood glucose was the only
significant predictor of symptomatic ICH by either definition (OR, 1.23; 95% CI, 1.03 to 1.48 per mmol/L increment;
P0.024). Contrast administration or dose was not associated with symptomatic ICH.
Conclusions—Intravenous iodinated contrast in doses typically required for CT angiography and perfusion imaging was not
associated with symptomatic intracranial hemorrhage in patients treated with alteplase. (Stroke. 2011;42:2170-2174.)
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Brain imaging has the potential to improve patient selec-tion for intravenous (IV) thrombolysis by excluding
from treatment those with predominantly irreversible ische-
mia and confining treatment to those with potentially viable
penumbra. Selection using MRI-based penumbral assessment
was associated with lower risk of symptomatic intracranial
hemorrhage (SICH) in prospective cohort studies.1,2 Multi-
modal CT imaging, comprising CT perfusion and CT angiog-
raphy in addition to noncontrast CT, offers an alternative
method of penumbral imaging that is potentially widely
applicable. However, analysis of the second Interventional
Management of Stroke II (IMS-2) study has suggested that
microcatheter injection of iodinated radiographic contrast
may increase the risk of intracranial hemorrhage (ICH) after
intra-arterial recombinant tissue-type plasminogen activator
(rtPA)3,4 independent of conventional predictors such as the
extent of hypoattenuation on CT scan, prior antiplatelet use,
and hyperglycemia.5–8 Similar findings were also reported in
a retrospective registry study by the same group.9 The IMS
investigators hypothesized that this effect may be due to
either contrast extravasation with toxicity to the blood–brain
barrier or physical trauma to the microvasculature consequent
to pressure of injections. Contrast doses in multimodal CT are
typically 100 to 150 mL, similar to those typically adminis-
tered during interventional revascularization procedures. The
issue of contrast-related risk is therefore pertinent to both
multimodal CT selection for IV therapy and for interventional
procedures.
We sought to determine whether IV contrast administered
for multimodal CT was related to SICH risk in a cohort of
patients treated with IV rtPA.
Methods
We reviewed data on all patients treated with IV rtPA at a single
comprehensive stroke center between May 2003 and the end of
November 2008. All patient data were entered into the Safe Imple-
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mentation of Thrombolysis in Stroke (SITS) register10–12 and had
follow-up brain imaging with CT approximately 24 hours after
treatment or sooner if their condition deteriorated. CT perfusion and
CT angiography were available at the discretion of the treating
clinician to support decision-making or were undertaken as part of
clinical research studies. All patients received IV rtPA in a National
Institute of Neurological Disorders and Stroke dose schedule (0.9
mg/kg total dose to a maximum of 90 mg).
Iodinated contrast of 2 types was used during the study period:
Xenetix 350 (iobitridol) since 2005 and Niopam (iopamidol) before
this. Contrast examinations were not performed in patients with a
glomerular filtration rate of 30 mL/min.
Data on patient age, pretreatment National Institutes of Health
Stroke Scale (NIHSS) score and blood glucose concentration, onset
to treatment time, and ICH type were extracted from the local SITS
database. Information on contrast exposure was obtained by review
of neuroradiology departmental records crossreferenced with imag-
ing reports and patient case notes. To include only contrast exposure
preceding, or concurrent with, IV thrombolysis, we included only
contrast CT examinations on the same date as the first CT. Standard
practice in the unit was for additional contrast CT examinations to be
performed either immediately before administration of the bolus of
alteplase or (where scans were undertaken for research purposes and
a treatment decision was made on noncontrast CT) immediately after
the bolus was administered but before the alteplase infusion was
started. Onset to treatment time therefore closely reflects the onset to
imaging time. Intra-arterial treatment was not routinely undertaken at
our center.
Definition of ICH
We categorized ICH according to the European and Australian
Cooperative Stroke Study (ECASS) classification13 incorporating
size and morphology to define hemorrhagic infarction Types 1 and 2
and parenchymal hematoma Types 1 and 2. We analyzed the
incidence of any ICH on follow-up imaging (hemorrhagic infarction
1 or 2 or parenchymal hematoma 1 or 2) and also SICH, which we
defined according to both the SITS-Monitoring Study (SITS-MOST;
deterioration of NIHSS score by 4 points within 24 hours of
treatment associated with parenchymal hematoma 2 on follow-up
imaging)12 and ECASS-2 (blood at any site on the CT scan in
combination with clinical deterioration or adverse events indicating
clinical worsening or causing a deterioration in the NIHSS score by
4 points.14) criteria.
Statistical Analysis
Statistical analysis was performed using SPSS 15 (SPSS Inc,
Chicago, IL) and STATSDIRECT (StatsDirect Ltd, Cheshire, UK)
software. For baseline data, Fisher exact test was used to compare
proportions in 22 tabulated data, normally distributed variables
were compared by unpaired t tests, and nonnormal data by Mann-
Whitney U tests. Binary logistic regression analysis was carried out
using SPSS to seek predictors of any ICH or SICH by both SITS and
ECASS-2 definitions. Univariate analysis included onset to treat-
ment time, treatment within 3 hours of onset, age, hypertension,
diabetes, atrial fibrillation, blood glucose, NIHSS score, systolic and
diastolic blood pressure, contrast dose, and contrast administration as
a binary variable. All variables with P0.1 in univariate analysis
were entered into a forward stepwise conditional model. Findings
were confirmed in a backward stepping model beginning with all
potentially predictive variables.
Results
Data from 319 consecutive patients were available, for whom
complete data on contrast use and follow-up imaging were
available on 312. One patient who had a rescue intra-arterial
procedure after initial IV thrombolysis was excluded from
analysis. No other patients had intra-arterial procedures. One
patient had received a 200-mL dose of contrast during
percutaneous coronary intervention that was performed im-
mediately before stroke onset. This patient subsequently had
an additional 150 mL of contrast during multimodal imaging.
Baseline clinical data for patients exposed to contrast and
those not exposed are summarized in Table 1. The patients
exposed to contrast were significantly younger and had a
lower rate of documented atrial fibrillation, but otherwise
there were no significant differences between the contrast-
exposed and nonexposed groups. Patients who had multi-
modal imaging were not treated significantly later than those
treated with noncontrast CT alone (174 minutes versus 169
minutes, P0.346).
Overall median NIHSS score pretreatment was 15 (inter-
quartile range, 9 to 19). The mean onset-to-treatment time
was 170 minutes.
The incidence of ICH of all radiological categories, or of
SICH by either ECASS-2 or SITS-MOST definitions, did not
differ between those who received IV contrast and those who
did not. Detailed comparison of relevant factors between
hemorrhage categories is described in Table 2.
In binary logistic regression analysis, univariate analysis
identified age, treatment within 3 hours, NIHSS score,
systolic blood pressure, and pretreatment blood glucose as
possible predictors. These were entered into multivariate
models together with contrast dose and contrast use as a
dichotomous variable. In multivariate regression, SICH by
ECASS-2 definition was associated with only pretreatment
blood glucose (OR, 1.20; 95% CI, 1.003 to 1.42 per mmol/L
increment; P0.046); presence of any ICH was associated
only with pretreatment NIHSS score (OR, 1.07; 95% CI, 1.03
to 1.12; P0.002). Use of contrast was not associated with
ICH risk by any definition.
Conclusions
The potential for multimodal imaging to improve clinical
outcomes by targeting thrombolytic treatment to those with a
perfusion scan signature of the ischemic penumbra, or to
extend the time window by identifying individuals with
viable tissue beyond conventional times, has been recognized
and partly supported by observational data that used MRI
definitions of penumbra.2 Multimodal CT imaging is increas-
ingly available as multidetector scanners with large detectors
proliferate and arguably has advantages over MRI in acces-
sibility and possibly patient safety (fewer contraindications,
shorter acquisition times, and an easier physiological moni-
toring environment). However, evidence in support of multi-
modal CT’s use is much less than for MRI, and it has other
safety issues, notably additional radiation exposure and sig-
nificant volumes of iodinated contrast administration. In
addition to rare allergic reactions, iodinated contrast admin-
istration may impair renal function and may be associated
with lactic acidosis in patients taking metformin. A hypothet-
ical concern that iodinated contrast may interfere with the
fibrinolytic properties of rtPA based on animal data was not
supported by a recent systematic review of clinical studies in
stroke,15 but this review was able to use only indirect
comparisons of recanalization rates and the possibility cannot
be excluded.
Recently, a possible increase in risk of ICH was reported to
be associated with the number of intra-arterial microcatheter
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injections of iodinated contrast in patients given combined IV
and intra-arterial thrombolytic treatment in the second IMS
trial.4 The IMS investigators considered that increased ICH
risk reflected loss of blood–brain barrier integrity and could
have resulted either from contrast toxicity or from pressure-
related damage consequent to microcatheter injections.4 The
first possibility raises concern about the increasing use of
iodinated contrast in multimodal CT in addition to interven-
tional revascularization procedures. The IMS-2 report used
the widest possible definition of ICH, including hemorrhagic
Table 1. Baseline Variables and Outcomes Stratified by Contrast Exposure
Clinical Features Contrast (n69) No Contrast (n243) P
Age, y (meanSD) 62.913.4 7012 0.0001
Male, no. (%) 35 (51) 155 (64) 0.052
Baseline NIHSS, median (IQR) 13 (8–15) 15 (10–20) 0.114
Serum glucose, mmol/L (meanSD) 6.72.7 6.81.8 0.899
Atrial fibrillation, no. (%) 13 (18.8) 81 (33.3) 0.030
Diabetes mellitus, no. (%) 4 (5.8) 26 (10.7) 0.257
Hypertension, no. (%) 33 (47.8) 138 (56.8) 0.217
Current smoker, no. (%) 23 (33.3) 58 (23.9) 0.122
Previous stroke, no. (%) 6 (8.7) 38 (15.6) 0.172
Initial systolic BP, mm Hg (meanSD) 143.630.8 147.826.8 0.3708
Initial diastolic BP, mm Hg (meanSD) 76.816.5 75.516.1 0.367
Treatment 3 h, no. (%) 40 (58) 181 (66.5) 0.201
Onset-to-treatment time, min (meanSD, median) 174.345 median 172.5 169.337 median 175 0.346
IA treatment, no. (%) 1 (1.4) 0 0.221
CTA only, no. (%) 15 (21.7) 0
CTP only, no. (%) 20 (29) 0
CTA and CTP, no. (%) 34 (49) 0
Contrast dose CTA, mL (meanSD) 58.53.7
Contrast dose CTP, mL (meanSD) 58.73.5
Total contrast dose, mL (meanSD) 110.98.6
Asymptomatic ICH, no. (%) 8 (11.6) 45 (18.5)
PH1, no. (%) 2 (2.8) 17 (6.8)
PH2, no. (%) 5 (7.2) 10 (4.1)
Symptomatic ICH (ECASS), no. (%), 95% CI 4 (5.8) (CI, 0.3 to 11.3) 12 (4.9) (CI, 2.2 to 7.7) 0.753
Symptomatic ICH (SITS-MOST), no. (%), 95% CI 3 (4.4) (CI,0.5 to 9.2) 9 (3.7) (CI, 1.3 to 6) 0.722
NIHSS indicates National Institute of Health Stroke Scale; IQR, interquartile range; BP, blood pressure; IA, intra-arterial; CTA,
computed tomography angiography; CTP, computed tomograpy perfusion; ICH, intracerebral hemorrhage; PH, parenchymal
hemorrhage; ECASS, European and Australian Cooperative Stroke Study; SITS-MOST, Safe Implementation of Thrombolysis in
Stroke-Monitoring Study; CI, confidence interval; SD, standard deviation.
Table 2. Comparison of Features by Hemorrhage Incidence*
ICH
Non-SICH Group Asymptomatic ICH ECASS-2 Definition SITS-MOST Definition
Total no. (%) 243 (77.9) 53 (17) 16 (5.1) 12 (3.8)
Age mean (95% CI), y 67.8 (66–69) 70 (66–74) 71.7 (65–78) 75.2 (70–80)
Admission blood glucose mean
(95% CI), mmol/L
6.7 (6.4–6.9) 6.9 (6.3–7.4) 7.9 (5.7–810.1) 8.2 (5.4–11)
Baseline NIHSS median (IQR) 14 (7–19) 17 (13–21) 18 (11–26) 18 (10–25)
No. treated within 3 h, (%) 156 (64.5) 37 (69.8) 7 (43.8) 4 (33.3)
Time to treatment mean (95% CI), min 171 (166–176) 166 (158–175) 165 (149–182) 177 (164–190)
No. receiving iodinated contrast, (%) 56 (23) 8 (15.1) 5 (31) 4 (33.3)
Contrast volume median, mL 100 60 110 110
ICH indicates intracerebral hemorrhage; SICH, symptomatic intracerebral hemorrhage; ECASS, European and Australian Cooperative
Stroke Study; SITS-MOST, Safe Implementation of Thrombolysis in Stroke-Monitoring Study; NIHSS,- National Institute of Health Stroke
Scale; IQR, interquartile range; CI, confidence interval.
*Patient characteristics in groups defined by presence of blood on follow-up imaging.
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infarction as well as the clinically important parenchymal
hematomas to increase the numbers for analysis. The IMS
group reported ICH of any type in 58% of their patients, a
considerably higher rate than the 22% that we found with a
similarly all-inclusive definition of ICH. Although greater
stroke severity and longer time to treatment of patients treated
in the IMS-2 study are expected to be associated with higher
ICH risk than in our population receiving IV treatment, and
other factors such as heparin use in IMS-2 study may also
contribute, the very large difference in reported rates raises
the possibility that the IMS-2 methodology resulted in over-
reporting of ICH, particularly hemorrhagic infarction, as a
consequence of minor local contrast extravasation being
indistinguishable from blood, something that was acknowl-
edged as a potential confounder by the investigators.
Animal studies have produced conflicting evidence on the
potential blood–brain barrier toxicity of contrast media.16,17
A recent study in transient middle cerebral artery occlusion in
rats reported that intra-arterial contrast administration, hepa-
rin administration, and coadministration of heparin and con-
trast significantly increased the incidence of cortical hemor-
rhage compared with control.18
It should be noted that our retrospective cohort of patients
is very different from those enrolled in the IMS trials. In the
IMS studies, the median NIHSS score at admission was
higher.3,19 The patients exposed to contrast in our study were
of a similar age to those in the IMS studies but the
noncontrast-exposed patients were significantly older. We
cannot therefore rule out a possible influence of contrast
administration in a more severe clinical population. Our study
also cannot address issues surrounding the intra-arterial
administration of contrast or the greater volumes of contrast
that may be administered if an intra-arterial procedure is
preceded by multimodal CT imaging.
After adjustment for baseline imbalance in relevant prog-
nostic factors between the contrast-exposed and nonexposed
groups, we found no association of either IV contrast admin-
istration or contrast dose with SICH in our series of patients
treated with IV rtPA. The only significant predictor of SICH
was pretreatment blood glucose, consistent with other obser-
vations5,8,20,21; both the PROACT II study and an analysis of
the SITS database have reported an association of pretreat-
ment hyperglycemia (thresholds of 200 mg/dL in Pro-
Urokinase for Acute Cerebral Thromboembolism [PROACT]
II and 180 mg/dL in SITS) with SICH,22,23 although an
analysis of the ECASS-2 trial suggested that sustained rather
than pretreatment hyperglycemia was the significant predic-
tor.6 Our SICH rates are within the 95% CI for incidence by
the ECASS-2 definition (4.6%; 4.1 to 5.1) but slightly
higher by the SITS-MOST definition compared with the
SITS-MOST series overall, possibly explained by an older
population and more severe pretreatment NIHSS scores.
Although the lack of association of IV contrast administration
with SICH is reassuring, the similar rates of SICH in contrast
and noncontrast groups (and possibly slightly higher rate of
parenchymal hematoma 2 categorized ICH in the contrast
group) despite these patients being younger and having less
severe strokes, together with the small absolute numbers of
SICH, indicates that replication of our findings in larger
series would be advisable. Our findings also cannot exclude
potential problems related to intra-arterial contrast use, in
which local concentrations will exceed those resulting from
IV bolus administration.
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